[3] Amico P., Evolution of graft survival in kidney transplantation: an analysis of the OPTN/UNOS Renal Transplant Registry, Clin. Transplant., 2010, 1–15
[4] Garcia-Garcia G., Harden P., Chapman J., For the world kidney day steering committee 2012., The global role of kidney transplantation, Nephrology., 2012, 17, 199–203 http://dx.doi.org/10.1111/j.1440-1797.2012.01564.x[Crossref]
[5] Persijn GG., Allocation of organs, particularly kidneys, within Eurotransplant, Hum. Immunol., 2006, 67, 419–423 [Crossref]
[6] Mayer G., Persijn GG., Eurotransplant kidney allocation system (ETKAS): rationale and implementation, Nephrol. Dial. Transpl., 2006, 21, 2–3 http://dx.doi.org/10.1093/ndt/gfi269[Crossref]
[8] Peng A., Vo A., Jordan SC., Transplantation of the highly human leukocyte antigen-sensitized patient: Long-term outcomes and future directions, Transplant. Rev., 2006, 20, 46 http://dx.doi.org/10.1016/j.trre.2006.06.002[Crossref]
[9] Warren DS., Montgomery RA., Incompatible kidney transplantation: Lessons from a decade of desensitization and paired kidney exchange, Immunol. Res. 2010, 47, 257 http://dx.doi.org/10.1007/s12026-009-8157-y[WoS][Crossref]
[10] Eikmans M., Waanders MM., Roelen DL., van Miert PP., Anholts JD., de Fijter HW., et al., Differential effect of pretransplant blood transfusions on immune effector and regulatory compartments in HLA-sensitized and nonsensitized recipients, Transplantation., 2010, 90, 1192–1199 http://dx.doi.org/10.1097/TP.0b013e3181fa943d[WoS][Crossref]
[11] Nicol D., MacDonald AS., Lawen J., Belitsky P., Early prediction of renal allograft loss beyond one year, Transpl. Int., 1993, 6, 153–157 http://dx.doi.org/10.1111/j.1432-2277.1993.tb00636.x[Crossref]
[12] Stanković B., Taseski J., Balint B., Trkuljić M., Veljančić V., Hrvačević R., et al., Značaj transfuzija krvi za razvoj citotoksičnih antitela kod bolesnika na hemodijalizi, Vojnosanit. Pregl., 2000, 57, 37–41
[13] Balasubramaniam GS., Morris M., Gupta A., Mesa IR., Thuraisingham R., Ashman N., Allosensitization Rate of Male Patients Awaiting First Kidney Grafts After Leuko-Depleted Blood Transfusion, Transplantation., 2012, 93, 418–422 http://dx.doi.org/10.1097/TP.0b013e3182419864[Crossref]
[14] Vaidya S., Synthesis of new and memory HLA antibodies from acute and chronic rejections versus pregnancies and blood transfusions, Transplant. P., 2005, 37, 648–649 http://dx.doi.org/10.1016/j.transproceed.2005.01.067[Crossref]
[15] Scornik JC., Ireland JE., Howard RJ., Pfaff WW., Assessment of the risk for broad sensitization by blood transfusions, Transplantation., 1984, 37, 249 http://dx.doi.org/10.1097/00007890-198403000-00006[Crossref]
[16] Sheldon S., Poulton K., HLA Typing and Its Influence on Organ Transplantation, Methods. Mol. Biol., 2006, 333, 157–174
[17] Petz B., Osnovne statističke metode, Zagreb: Izdanja škole narodnog zdravlja “Andrija Štampar”, 1964, 111–133
[18] Morales-Buenrostro LE., Terasaki PI., Marino-Va’zquez LA., et al., “Natural” human leukocyte antigen antibodies found in nonalloimmunized healthy males, Transplantation., 2008, 86, 1111 http://dx.doi.org/10.1097/TP.0b013e318186d87b[Crossref]
[19] Susal C., Dohler B., Sadeghi M., et al., HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: A collaborative transplant study report, Transplantation., 2009, 87, 1367 http://dx.doi.org/10.1097/TP.0b013e3181a24073[Crossref]
[20] Terasaki PI., Cai J., Human leukocyte antigen antibodies and chronic rejection: From association to causation, Transplantation., 2008, 86, 377 http://dx.doi.org/10.1097/TP.0b013e31817c4cb8[Crossref]
[22] Wolfe RA., Ashby VB., Milford EL., et al., Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant, New. Engl. J. Med., 1999, 341, 1725 http://dx.doi.org/10.1056/NEJM199912023412303[Crossref]
[24] Hrvačević R., et al., Predijalizna transplantacija bubrega, Vojnosanit. Pregl., 2002, 59, 423–427 http://dx.doi.org/10.2298/VSP0204423H[Crossref]
[25] Sanfilippo FP., Bollinger RR., MacQueen JM., Brooks BJ., Koepke JA., A randomized study comparing leukocyte-depleted versus packed red cell transfusions in prospective cadaver renal allograft recipients, Transfusion., 1985, 25, 116–119 http://dx.doi.org/10.1046/j.1537-2995.1985.25285169200.x[Crossref]
[26] Karpinski M., Pochinco D., Dembinski I., Laidlaw W., Zacharias J., Nickerson P., Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates, J. Am. Soc. Nephrol., 2004, 15, 818–824 http://dx.doi.org/10.1097/01.ASN.0000115399.80913.B1[Crossref]
[27] Vamvakas EC., Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions, Transfus. Med. Rev., 1998, 12, 258–270 http://dx.doi.org/10.1016/S0887-7963(98)80002-3[Crossref]
[28] Scornik JC., Meier-Kriesche H-U., Blood Transfusions in Organ Transplant Patients: Mechanisms of Sensitization and Implications for Prevention, Am. J. Transplant., 2011, 11, 1785–1791 http://dx.doi.org/10.1111/j.1600-6143.2011.03705.x[Crossref]
[29] Bilgin YM., van de Watering LM., Brand A., Clinical effects of leucoreduction of blood transfusions, Neth. J. Med., 2011, 69(10), 441–450
[30] Marfo K., Lu A., Ling M., Akalin E., Desensitization protocols and their outcome, Clin. J. Am. Soc. Nephro., 2011, 6, 922–936 http://dx.doi.org/10.2215/CJN.08140910[Crossref]